Carmetizide is benzothiadiazine derivative patented by pharmaceutical company Abbott Laboratories as a diuretic. In preclinical studies, Carmetizide demonstrates perfect safety profile. Administration of Carmetizide (10,000 mg/kg, orally or 5000 mg/kg, s.c. or i.p.) to rats had no toxic effect. Carmetizide had no effect on the central nervous system and the cardiovascular system of guinea pigs or on the heart-lung preparation of dogs. These drugs did not affect the body temperature of rats and the blood coagulation of rabbits. Carmetizide had no effect on the spontaneous movement of smooth muscles.